## **Monoclonal Antibodies** for treatment of COVID-19

November 25, 2020




In November, the U.S. Food and Drug Administration issued an Emergency Use Authorization to allow the use of monoclonal antibodies for the treatment of mild to moderate symptoms of COVID-19 in adults and pediatric patients.

## What are monoclonal antibodies?

Monoclonal antibodies are laboratory-made proteins that mimic your immune system's ability to fight off harmful viruses. Bamlanivimab and casirivimab + imdevimab are monoclonal antibodies that are specifically designed to protect against the spike protein of COVID-19. These proteins are designed to stop the virus from entering the human cells.

## Who can get this treatment?

To receive the treatment you must be in one of the high risk categories:




- High BMI
- Sickle cell disease
- Heart disease
- Neurodevelopment disorders
- A medical related dependence
- Chronic respiratory diseases
- Asthma



- Cardiovascular disease
- Hypertension
- Chronic respiratory diseases












These medications are **NOT** approved for use in patents who are hospitalized due to COVID-19 or require oxygen therapy. Benefits of treatment have not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies may be associated with worse clinical outcomes when given to patients with COVID-19 requiring oxygen ventilation. Individual administration sites may have additional criteria for use of these monoclonal antibody therapies in patients.


## **Treatment locations**

Open the camera app Focus the camera on the QR code Follow the instructions to see locations



These medications will be available at **no cost** to patients, although health care facilities may charge for administering the medicine.





For more information contact:

Arkansas Department of Health 1-800-803-7847 ADH.CoronaVirus@arkansas.gov